-- Scott Roberts
MONDAY, June 23, 2014 (HealthDay News) -- The antibiotic
Sivextro (tedizolid phosphate) has been approved by the U.S. Food
and Drug Administration to treat adults with serious or
life-threatening skin infections.
The drug, which may be taken intravenously or by a pill, is
designed to treat infections including methicillin-resistant
Staphylococcus aureus(MRSA), the FDA said in a news
The drug's safety and effectiveness were evaluated in clinical
studies involving more than 1,300 adults with serious-to-severe
skin infections. The most common side effects recorded were nausea,
headache, diarrhea, vomiting and dizziness. The drug was not
evaluated among adults with below-normal counts of germ-fighting
white blood cells, the agency said.
Sivextro is the second new antibiotic for skin infections to be
FDA-approved in the past month, following the May 23 approval of
Sivextro is marketed by Cubist Pharmaceuticals, baaed in
To learn more about this approval, visit the
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.